 | Up a level |
2020
Fraser, Graeme, Chanan-Khan, Asher, Demirkan, Faith, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy, Dilhuydy, Marie Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlosky, Miguel, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Balasubramanian, Sriram, Howes, Angela and Cramer, Paula (2020). Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Leuk. Lymphoma, 61. S. 106 - 109. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403
2019
Lavezzi, Silvia Maria, de Jong, Jan, Neyens, Martine, Cramer, Paula, Demirkan, Fatih 
ORCID: 0000-0002-1172-8668, Fraser, Graeme, Bartlett, Nancy ORCID: 0000-0001-8470-394X, Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Goy, Andre ORCID: 0000-0001-5125-6522, Ganguly, Siddhartha, Salman, Mariya, Howes, Angela, Mahler, Michelle, De Nicolao, Giuseppe and Poggesi, Italo
(2019).
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Pharm. Res., 36 (7).
NEW YORK:
SPRINGER/PLENUM PUBLISHERS.
ISSN 1573-904X
2017
Hallek, Michael, Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Mahler, Michelle, Phelps, Charles, Salman, Mariya, Howes, Angela and Chanan-Khan, Asher
(2017).
Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study.
Leuk. Lymphoma, 58.
S. 192 - 195.
ABINGDON:
TAYLOR & FRANCIS LTD.
ISSN 1029-2403
2015
Chanan-Khan, Asher, Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Masha, Howes, Angela and Hallek, Michael
(2015).
Ibrutinib combined with bendamustine/rituximab (BR) in previously treated small lymphocytic lymphoma (SLL): analysis of patients in the HELIOS trial.
Leuk. Lymphoma, 56.
S. 92 - 94.
ABINGDON:
TAYLOR & FRANCIS LTD.
ISSN 1029-2403
Fraser, Graeme, Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Masha, Howes, Angela and Hallek, Michael
(2015).
Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial.
Leuk. Lymphoma, 56.
S. 98 - 101.
ABINGDON:
TAYLOR & FRANCIS LTD.
ISSN 1029-2403